Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
The investigational drugs E7820, indisulam and tasisulam (aryl-sulfonamides) promote the degradation of the splicing factor RBM39 in a proteasome-dependent mechanism. While the activity critically depends on the cullin RING ligase substrate receptor DCAF15, the molecular details remain elusive. Here...
Saved in:
Published in | Nature chemical biology Vol. 16; no. 1; pp. 7 - 14 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.01.2020
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The investigational drugs E7820, indisulam and tasisulam (aryl-sulfonamides) promote the degradation of the splicing factor RBM39 in a proteasome-dependent mechanism. While the activity critically depends on the cullin RING ligase substrate receptor DCAF15, the molecular details remain elusive. Here we present the cryo-EM structure of the DDB1–DCAF15–DDA1 core ligase complex bound to RBM39 and E7820 at a resolution of 4.4 Å, together with crystal structures of engineered subcomplexes. We show that DCAF15 adopts a new fold stabilized by DDA1, and that extensive protein–protein contacts between the ligase and substrate mitigate low affinity interactions between aryl-sulfonamides and DCAF15. Our data demonstrate how aryl-sulfonamides neo-functionalize a shallow, non-conserved pocket on DCAF15 to selectively bind and degrade RBM39 and the closely related splicing factor RBM23 without the requirement for a high-affinity ligand, which has broad implications for the de novo discovery of molecular glue degraders.
Cryo-EM and crystal structural analysis of DDB1–DCAF15–DDA1 in complex with E7820 and RBM39 reveal that aryl-sulfonamides reshape the surface of the cullin RING ligase substrate receptor DCAF15 to bind and degrade the splicing factor RBM39. |
---|---|
Bibliography: | USDOE Office of Science (SC) Damon Runyon Cancer Research Foundation NIH-ORIP HEI National Institutes of Health (NIH) AC02-06CH11357; NCI R01CA214608; 1F32CA232772-01; DRR-50–18; P41 GM103403; S10 RR029205 NIH NIGMS These authors contributed equally to this work. Author contributions: T.F., H.Y., N.S.G., R.P.N., and E.S.F. initiated the project and designed experiments. T.F., H.Y. and R.P.N. conducted protein purification, T.F. performed crystallization and cryo-EM experiments. H.Y. developed and performed biochemical assays. R.P.N., T.F. and E.S.F. collected and processed X-ray diffraction data. N.A.E. and K.A.D. performed the mass spectrometry experiments. H.Y., Z.L., and Q.C. synthesized small molecules with input from T.Z. N.S.G. and E.S.F. supervised the project. T.F., H.Y., and E.S.F. wrote the manuscript, with input from all authors. |
ISSN: | 1552-4450 1552-4469 |
DOI: | 10.1038/s41589-019-0378-3 |